DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR EGRIFTA
All Clinical Trials for Egrifta
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00608023 | TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy | Completed | Theratechnologies | Phase 3 | 2007-08-01 | HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation, loss of extremity and subcutaneous fat, in association with dyslipidemia and insulin resistance. Data from the first Phase 3 multicenter, randomized, placebo-controlled trial demonstrated that daily administration of 2mg TH9507, a growth hormone releasing factor (GRF), to HIV- infected patients with excess of abdominal fat accumulation for 26 weeks resulted in decreases in visceral adipose tissue (VAT) and trunk fat, with lesser changes in limb fat and subcutaneous adipose tissue (SAT). The present study is aimed at confirming the observations made during the first Phase 3 study. |
NCT01579695 | Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® | Recruiting | Theratechnologies | N/A | 2013-02-01 | The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®. |
NCT01591902 | Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® | Recruiting | Theratechnologies | Phase 4 | 2012-06-01 | To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Egrifta
Condition Name
Clinical Trial Locations for Egrifta
Trials by Country
Clinical Trial Progress for Egrifta
Clinical Trial Phase
Clinical Trial Sponsors for Egrifta
Sponsor Name